Cardiac amyloidosis as a potential risk factor for transapical transcatheter aortic valve implantation.
Transcatheter aortic valve implantation via transarterial or transapical access is an alternative therapy to treat high-risk patients with severe symptomatic aortic stenosis. Despite growing experience, procedural complications may still occur. We herein report an 86-year-old female patient with fatal left ventricular rupture after transapical transcatheter aortic valve implantation with an Edwards Sapien prosthesis due to severe cardiac amyloidosis.